Risk adjusted net present value: What is the current valuation of Pharma Mar’s Ecubectedin?
Pharmaceutical Technology
JUNE 6, 2023
Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Buy the model here. It is administered through intravenous route.
100 
Let's personalize your content